

capable of raising neutralizing antibodies against in vivo challenge by a pathogen, wherein said derivative:

- (a) is devoid of the membrane-binding domain whereby the derivative is free of membrane, and
- (b) has exposed antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by the pathogen.
2. An immunogenic composition according to Claim 16 wherein the derivative is a derivative of glycoprotein D.
3. An immunogenic composition according to Claim 16 wherein the derivative is a derivative of glycoprotein C.
4. An immunogenic composition according to Claim 16 wherein the derivative is a derivative of glycoprotein A/B.
5. An immunogenic composition according to Claim 16 wherein said immunogenic composition comprises a mixture of glycoproteins or glycoprotein derivatives.
6. An immunogenic composition according to Claim 5 wherein said mixture comprises glycoprotein C or a derivative thereof and glycoprotein D or a derivative thereof.
7. An immunogenic composition according to Claim 5 wherein said mixture comprises glycoprotein D or a derivative thereof.
8. An immunogenic composition according to Claim 7 wherein said mixture further comprises glycoprotein B or a derivative thereof.
10. A method of producing an immunogenic composition according to any one of Claims 1, 2, 3, or 4, said method comprising preparing a nucleic acid encoding said derivative, incorporating said nucleic acid into an expression vector, introducing said vector into a host cell, and collecting the derivative as a secretion product.
11. A method according to Claim 10 wherein the host cell is a stable eukaryotic cell line.
12. A method according to Claim 11 wherein the host cell is a mammalian cell line.
13. A method according to Claim 11 wherein the cell line is deficient in the production of dhfr and the vector contains a dhfr selectable marker.

14. A method according to Claim 10 wherein the derivative is a glycoprotein D of herpes simplex virus type 1 or type 2.

15. A method according to Claim 14 wherein the derivative comprises the first 300 amino acid residues of the glycoprotein D.

Please add the following claims:

16. An immunogenic composition according to Claim 1 wherein the derivative is a derivative of a herpes glycoprotein.

17. An immunogenic composition according to Claim 16 wherein the derivative is a derivative of herpes simplex virus type 1 or type 2, and the pathogen is herpes simplex type 1 and/or type 2.

18. An immunogenic composition according to Claim 16 wherein said derivative is produced in a stable eukaryotic cell line.

19. An immunogenic composition according to Claim 18 wherein said cell line is a mammalian cell line.

20. An immunogenic composition according to Claim 2 wherein said derivative comprises the first 300 residues of glycoprotein D.

21. A method according to Claim 10 wherein the derivative is a derivative of glycoprotein C.

22. A method according to Claim 10 wherein the derivative is a derivative of glycoprotein A/B.

23. A nucleic acid encoding a truncated, membrane-free derivative of a polypeptide comprising a membrane-binding domain and antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by a pathogen, wherein said derivative is:

- (a) is devoid of the membrane-binding domain whereby the derivative is free of membrane, and
- (b) has exposed antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by the pathogen.

24. The nucleic acid of Claim 23 wherein the derivative is a derivative of a herpes glycoprotein.